Session: OR26-Pituitary Tumorigenesis: Advances in Mechanism & Treatment
Room 130 (Moscone Center)
Thirty one sporadic somatotropinomas with no AIP mutations with low (n=13) or high (n=18) AIP protein expression were analyzed for expression of AIP mRNA and 13 miRs predicted to bind the 3’UTR of AIP using RT-qPCR. A luciferase reporter assay was used to study the effect of selected miRs on 3’UTR of AIP in GH3 cells. miRs with significant effect were further studied following introduction of mutations at the predicted miR binding sites.
There was no significant difference in AIP mRNA expression between tumors with low or high AIP expression. This suggests that the expression of AIP protein might be regulated post-transcriptionally. One of the possible mechanisms is via miRs, which can repress protein expression by inhibiting translation. Out of the strictly selected predicted miRs, (let-7b, let-7a, miR-202, -22, -31, -324, -34a, -34c, -449, -510, -612, -639, -671) the expression of miR-22 and miR-34a was higher in tumors with low AIP expression than in tumors with high AIP expression (2.5x for miR-22, p=0.046 and 3x for miR-34a, p=0.022). Co-transfection of miR-34a precursor and the luciferase-WT-AIP-3’UTR plasmid construct showed a significant negative effect on the luciferase expression (31±4% decrease, p<0.001), suggesting that miR-34a binds to the AIP-3’UTR, while miR-22 showed no inhibition. miR-34a is predicted in silico to interact with 3 different specific target sequences located within the 3’-UTR of AIP. By using deletion mutants of each of these 3 sites, we have identified the c.*6-30 target site to be involved in miR-34a’s activity, as mutation of this binding site completely abolished the inhibitory effect of miR-34a on luciferase activity.
We have identified and proved that miR-34a is a negative regulator of AIP protein expression and hypothesized that miR-34a could be responsible for the low AIP expression observed in half of somatotropinomas which can lead to invasive phenotype and resistance to SSA.
Nothing to Disclose: GT, LK, JD, LMC, MD, MG, MK
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters